ALX Oncology Holdings Inc. (Nasdaq: ALXO) reported its financial results for the third quarter ended September 30, 2026, and provided an update on its clinical development programs. The company announced that its cash, cash equivalents, and investments totaled $147.2 million as of September 30, 2026. ALX Oncology stated that this cash balance is sufficient to fund planned operations through the first half of 2028.
For the three months ended September 30, 2026, the company reported a GAAP net loss of $21.8 million, or $0.15 per basic and diluted share. This compares to a GAAP net loss of $22.1 million, or $0.41 per share, for the same period in the prior year. Research and development expenses for the quarter were $17.5 million, while general and administrative expenses were $5.5 million.
In terms of clinical updates, ALX Oncology highlighted progress on its ASPEN-09-Breast trial. This Phase 2 study evaluates evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer. The company expects to report topline data from approximately 120 patients in the second half of 2027. Additionally, the company anticipates reporting safety and early efficacy data from the Phase 1 dose-escalation study of its EGFR-targeted antibody-drug conjugate, ALX2004, in December 2026. A Key Opinion Leader webinar is planned to review the results from 35 patients enrolled in the ALX2004 study to date.